Shionogi divests US pediatrics as Osphena takes center stage
This article was originally published in Scrip
Executive Summary
Shionogi says its decision to offload three pediatric drugs in its US commercial portfolio to Concordia Pharmaceuticals reflects a desire to focus on core products and major pipeline projects in the women's health and pain areas.